Objective
Milk protein peptides can inhibit angiotensin-I-converting enzyme (ACE) Drugs, which inhibit ACE, are in widespread use in cardiovascular medicine. Little or no information is available on the physiological efficacy in man of ingesting natural milk protein peptides/hydrolysis's, which inhibit ACE in vitro. Therefore, it is proposed to address this European-wide functional food ingredient problem/opportunity. The proposal objectives are to perform a detailed physiological, physicochemical, immunochemical and catechetical characterisation, in addition to a consumer assessment of these naturally derived inhibitors of ACE. Milk proteins will be hydrolysed using food-grade proteases. Clinical/bio availability trials will be performed in human volunteers. Immunochemical studies will use serum samples from humans fed ACE inhibitory hydrolysis. Catechetical studies will use human cell culture systems. Consumer awareness will be assessed on a global basis. The outcome of this proposal should lead to the development of clinically validated health claims in respect to the physiological efficiency and safety of ingesting milk protein-derived inhibitors of ACE.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Call for proposal
Data not availableFunding Scheme
CSC - Cost-sharing contractsCoordinator
61 LIMERICK
Ireland